What supervised deprescribing is worth to your practice
CMS confirmed in May 2026 that the clinical work of a supervised taper counts as billable time under existing chronic care management codes, and that contracted clinical staff working under your general supervision can furnish it. This models what that means for your Medicare panel. Adjust the inputs to match your practice.
Your practice
Defaults describe a three-physician primary care practice with a typical Medicare panel.
Your panel
Roughly 600 per full-time PCP.
Benzodiazepines, z-drugs, anticholinergics, or CNS-active polypharmacy.
Of those flagged. Referral from the patient's own physician converts better than cold outreach.
How many months of care-management time you bill during one taper episode.
Accounts for denials and uncollected 20% patient coinsurance.
99490 + 99439 · 6 billable months · 93% collected
Year one net collections
$87,812
From 135 patients tapering, at roughly $650 collected per completed episode.
How the panel narrows
See what this looks like on your actual panel
We will run these numbers against your real Medicare population and walk through how the workflow would fit your practice. No cost, no obligation.
Rates are 2026 national averages and vary by locality under the geographic practice cost index. Verify against the CMS Physician Fee Schedule Look-Up Tool for your area.
CCM requires an initiating visit plus documented patient consent, two or more chronic conditions expected to last twelve months, and an electronic care plan. Deprescribing time counts toward the code; it does not replace its requirements.
APCM is mutually exclusive. If a patient is enrolled in Advanced Primary Care Management, CCM and PCM cannot be billed for that patient in the same month. Choose one path per patient.
No double billing against Part D. Deprescribing work already paid as medication therapy management under Part D cannot also be billed to the Physician Fee Schedule.
Complex CCM carries documentation risk. 99487 requires moderate or high complexity medical decision making and substantial care plan revision. It is modeled as available, not assumed.
Remote monitoring is excluded from this model. RPM requires physiologic device data on 16 of 30 days; symptom check-ins alone do not qualify. Treat any RPM or RTM revenue as upside to be verified separately.